This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| A. Classification codes | ICD-10 C43 (C43.0–C43.9 by site; C43.9 melanoma of unspecified site) |
| B. Synonyms | Malignant melanoma, cutaneous melanoma, malignant melanoma, acral lentiginous melanoma (acral melanoma), nodular melanoma, superficial spreading melanoma, lentigo maligna melanoma |
| C. Adult onset | Very high — occurs mainly in adults in their 30s–60s; in Korea and Asia, acral melanoma can occur at any age |
| Special Copayment Reduction | V193 · 5 years from the cancer patient registration date · 5% copayment |
| 1. History | First described by Hippocrates; René Laennec named melanoma (1812); UV–melanoma association established; surge in incidence in Australia |
| 2. Causes | Ultraviolet radiation (UV-A, UV-B); tanning beds (PUVA); family history; multiple nevi; albinism; immunosuppression; acral melanoma in Korea and Asia is unrelated to UV |
| 3. Genetics | BRAF V600E (about 50%); NRAS (about 20%); KIT (acral, mucosal); NF1 (about 15%); BRAF+MEK inhibitor targets; PD-L1/TMB immunotherapy |
| 4. Epidemiology | High incidence in the West (Australia, Europe, USA); low but increasing in Korea and Asia; acral melanoma accounts for 40–60% in Asia |
| 5. Pathophysiology | UV → melanocyte DNA damage (CPD, 6-4PP) → BRAF/NRAS mutation → constitutive activation of the MAPK pathway → malignant melanoma |
| 6. Symptoms | Asymmetry, irregular border, color variegation, diameter >6mm, and evolution of pigmented lesions (ABCDE); bleeding and itching; satellite nodules |
| 7. Signs | Abnormal dermoscopy findings; lymphadenopathy; cutaneous satellite lesions; hepatomegaly and neurological abnormalities with metastasis |
| 8. Screening | Regular skin self-examination; full-body skin examination for high-risk groups (once a year); dermoscopy; early regular screening for those with a family history |
| 9. Diagnosis | Excisional biopsy or wide excisional biopsy; sentinel lymph node biopsy (SLNB); BRAF/NRAS/KIT/PD-L1 testing; AJCC TNM staging (8th edition) |
| 10. Treatment | Wide local excision; adjuvant pembrolizumab/nivolumab; BRAF V600E: dabrafenib+trametinib; ipilimumab+nivolumab |
| 11. Prognosis | Stage I 5-year survival 97–99%; stage II 65–85%; stage III 40–78%; stage IV 5-year survival 25–35% (improved since the immunotherapy era) |
| 12. Prevention | UV protection (sunscreen SPF30 or higher); no tanning beds; protective clothing; regular skin examinations; ABCDE education |
| 13. References | NCCN melanoma guidelines, ASCO, ESMO, Korean Dermatological Association, PMC papers on melanoma in Koreans |
Malignant melanoma is a malignant skin tumor originating from melanocytes, and its existence has been recognized since antiquity. Hippocrates's description of a "black tumor (melas tumor)" around 460 BC is regarded as the first historical record of melanoma. In the 18th century, a tumor surgically removed by John Hunter in 1787 was later identified as melanoma.
In 1812, the French physician René Laennec used the term "mélanose," beginning the modern pathological description of melanoma. In the 19th–20th centuries, melanoma was established as a metastatic tumor, and surgical excision was performed as the main treatment. In 1941, the American surgeons Pringle and Pache established the principle of wide excision.
The association between ultraviolet (UV) radiation and melanoma was established through epidemiological studies in the mid-20th century. As incidence rose sharply in regions with high UV exposure such as Australia and New Zealand, UV was shown to be the most important environmental risk factor. With the popularization of tanning beds in the 1970s–1990s, melanoma incidence among young people increased, and in 2009 the WHO classified tanning beds as a Group 1 carcinogen.
In the history of treatment, 2011 was a revolutionary turning point. Ipilimumab (anti-CTLA-4 antibody) became the first agent to demonstrate improved overall survival in metastatic melanoma, opening the era of immuno-oncology therapy. In the same year, vemurafenib (BRAF V600E inhibitor) was also approved, so targeted therapy and immunotherapy arrived simultaneously. Subsequently, with the approval of PD-1 inhibitors such as pembrolizumab and nivolumab, the 5-year survival rate of melanoma improved dramatically.
In Korea, melanoma has a lower incidence than in the West, but it shows the distinctive epidemiological feature that acral lentiginous melanoma (ALM) accounts for about 40–60% of all melanomas. This suggests a pathogenesis unrelated to UV exposure and is an important theme in melanoma research in Korea and Asia.
The causes of melanoma are broadly divided into UV-related and non-UV-related factors.
Ultraviolet radiation (UV-A and UV-B) is the most important environmental risk factor for melanoma. UV-B (280–315nm) causes direct damage to melanocyte DNA, forming cyclobutane pyrimidine dimers (CPD) and 6-4 photoproducts. These cause C→T or CC→TT mutations ('UV signature mutation'), leading to oncogenic mutations in genes such as BRAF and NRAS. UV-A emitted from tanning beds (PUVA) is also known to increase the risk of melanoma 2–4-fold.
Fair skin, red or blond hair, and freckles are phenotypic factors that make the skin vulnerable to UV damage. The risk of melanoma increases with multiple dysplastic nevi, and the risk is markedly higher with more than 100 nevi. Giant congenital melanocytic nevi also carry a risk of malignant transformation.
In familial melanoma, germline variants in CDKN2A (p16) and CDK4 are involved, with a lifetime risk reaching 50–90%. BRCA2 germline variants also slightly increase melanoma risk. Xeroderma pigmentosum is a hereditary disease in which a defect in DNA damage repair dramatically increases the risk of melanoma and other skin cancers.
Acral melanoma, common in Korea and Asia, occurs on the palms and soles and under the nails and is unrelated to UV exposure. Repeated mechanical stimulation, trauma, and friction at these sites have been proposed as risk factors. Immunosuppression (HIV/AIDS, after organ transplantation) also increases melanoma risk.
BRAF V600E mutations are found in about 50% of melanomas, 90% of which are the V600E mutation. BRAF V600E constitutively activates the MEK-ERK (MAPK) signaling pathway, promoting cell proliferation. It is the key target of combined targeted therapy with BRAF inhibitors (vemurafenib, dabrafenib) and MEK inhibitors (trametinib, cobimetinib). NRAS mutations are found in about 20% and simultaneously activate the RAS-MAPK and PI3K pathways. NRAS-mutant melanoma is resistant to BRAF inhibitors, and MEK inhibitors show partial efficacy.
KIT mutations and amplifications are found specifically in acral and mucosal melanomas (about 20–30%). KIT inhibitors such as imatinib and nilotinib are effective in some KIT-mutant melanomas. NF1 mutations are found in about 15% and cause hyperactivation of the MAPK pathway. GNAQ/GNA11 mutations are found in 90% of uveal melanomas but are rare in cutaneous melanoma.
Because of UV-induced mutations, melanoma is one of the tumors with the highest tumor mutational burden (TMB) among all cancer types. High TMB increases neoantigen generation, enhancing responsiveness to immune checkpoint inhibitors. PD-L1 expression is also a predictor of immunotherapy response, but integrated use with TMB is recommended. Mismatch repair deficiency (MMR deficiency) occurs in some melanomas and is an indication for pembrolizumab.
The incidence of melanoma varies greatly by geography and race. Australia and New Zealand have the highest incidence in the world (30–60 per 100,000 population), while Europe and the United States are at about 10–20. In contrast, in Korea and other Asian countries it is markedly lower at 1–3. However, Korea too has shown a steadily increasing trend over the past 20 years.
The most important epidemiological feature of melanoma in Korea is that acral lentiginous melanoma (ALM) accounts for about 40–60% of all cases. This contrasts sharply with the proportion of ALM in the West (3–5%). Other common subtypes of melanoma in Korea include superficial spreading melanoma (SSM), nodular melanoma (NM), and lentigo maligna melanoma (LMM). The median age at onset in Korea is in the 60s–70s, somewhat older than in the West (50s). The male-to-female ratio in Korea is close to 1:1, and unlike in the West, it occurs anywhere on the skin of the body.
Melanoma develops through a process of multistep melanocyte transformation.
When UV-B photons are absorbed by melanocyte DNA, cyclobutane dimers (CPD) form between adjacent pyrimidines. If the nucleotide excision repair (NER) mechanism fails to repair them, C→T mutations become fixed during DNA replication. These UV-specific mutations cause the T>A mutation at BRAF codon 600 (T1799A, V600E), constitutively activating the MEK-ERK pathway. Subsequently, TERT promoter mutations, CDKN2A deletion, PTEN loss, and others accumulate sequentially, leading to invasive melanoma.
In ALM, UV-specific mutations are rare; instead, KIT mutations, CDK4 amplification, and CCND1 amplification are relatively common. A pathway in which repeated mechanical friction or pressure on the palms and soles induces inflammation and DNA damage has been proposed as a hypothesis but has not yet been fully elucidated. Complex genomic rearrangements (structural variants) are observed particularly frequently in ALM.
In the tumor microenvironment, PD-L1 overexpression suppresses the antitumor response of CD8+ T cells. Impaired antigen presentation (loss of HLA-I expression) and increased secretion of immunosuppressive cytokines (TGF-β, IL-10) also contribute to immune evasion. This provides the mechanistic rationale for immune checkpoint inhibitor therapy (anti-PD-1, anti-CTLA-4).
The ABCDE rule is widely used to evaluate the clinical symptoms of cutaneous melanoma:
Bleeding occurs spontaneously or with minor irritation in nodular melanoma or advanced lesions. Pruritus (itching) may occur in rapidly growing lesions. In acral melanoma, a longitudinal black band under the nail (longitudinal melanonychia) is characteristic, and periungual pigmentation (Hutchinson's sign) suggests malignancy. In advanced cases, symptoms of satellite nodules, local metastasis, lymphadenopathy, and distant metastasis appear.
On physical examination, pigmented lesions meeting the ABCDE criteria are found. Dermoscopy is more sensitive than naked-eye examination, and melanoma-specific findings such as an atypical pigment network, irregular streaks, blue-white veil, and regression structures are observed. In acral melanoma, an irregular parallel ridge pattern on dermoscopy is characteristic.
Enlargement of the sentinel lymph node or regional lymph nodes is palpable. Satellite metastases and in-transit metastases are metastatic lesions appearing in the skin or subcutaneous tissue between the primary tumor and the lymph nodes. Hepatomegaly with liver metastasis, focal neurological deficits with brain metastasis, and cough and dyspnea with lung metastasis may occur. In metastatic melanoma, elevated serum LDH is an indicator of poor prognosis.
National melanoma screening of the general population is currently not recommended in most countries. However, regular full-body skin examination is recommended in the following high-risk groups:
For the general public, the method of skin self-examination is taught, and people are advised to see a dermatologist immediately when changes meeting the ABCDE criteria occur. Tracking changes in nevi using total body photography + dermoscopy is effective in high-risk groups.
Excisional biopsy is the standard; when melanoma is suspected, the lesion is completely excised with a 1–2mm margin for pathological examination. Punch biopsy and shave biopsy are not recommended, and punch biopsy in particular interferes with measurement of Breslow thickness. For subungual lesions, longitudinal biopsy is preferred.
The pathology report includes histological subtype, Breslow thickness (mm), presence of ulceration, mitotic rate, neural, vascular, and lymphatic invasion, and margin status. For molecular testing, BRAF V600 mutation (PCR or NGS), NRAS, KIT, NTRK mutation testing, PD-L1 expression, and TMB measurement are needed to determine the treatment plan.
In melanomas of T1b or higher with Breslow thickness ≥0.8mm or ulceration, sentinel lymph node biopsy is performed to evaluate lymph node micrometastasis. After local anesthesia, the sentinel lymph node is identified using a radioisotope (Tc-99m sulfur colloid) and blue dye and is excised. SLNB results are central to staging and decisions on adjuvant treatment.
In stage III or higher, distant metastasis is evaluated with PET-CT or chest, abdomen, and pelvis CT. Head MRI is essential for evaluating brain metastasis. The treatment plan is determined according to AJCC 8th edition TNM staging (stages I–IV).
Wide local excision (WLE) is the primary treatment for melanoma. Recommended excision margins are in situ: 0.5–1cm, T1 (thickness ≤1mm): 1cm, T2–T3 (1–4mm): 1–2cm, T4 (>4mm): 2cm. In Korea, ALM (acral melanoma) may require amputation of toes or fingers, and there are study results showing that slow Mohs surgery is useful in ALM for reducing recurrence and minimizing defect size.
| AJCC stage | 5-year survival | Key prognostic factors |
|---|---|---|
| Stage IA (T1a, N0, M0) | 97~99% | Thickness ≤0.8mm, no ulceration |
| Stage IB (T1b-T2a) | 90~95% | Thickness ≤2mm |
| Stage IIA (T2b-T3a) | 80~85% | Thickness 1–4mm |
| Stage IIB (T3b-T4a) | 70~75% | Presence of ulceration important |
| Stage IIC (T4b) | 55~65% | Thickness >4mm + ulceration |
| Stage III (N+, M0) | 40~78% | Number of lymph node metastases, satellite/in-transit metastases |
| Stage IV (M1) | 25–35% (5-year; immunotherapy era) | Site of metastasis (lung > brain > liver), LDH |
In the era before immuno-oncology therapy, the 5-year survival rate of metastatic melanoma was less than 5–10%, but with combined ipilimumab+nivolumab treatment, the 5-year survival rate has improved to 52%. Breslow thickness, presence of ulceration, mitotic rate, and lymph node metastasis are the most important prognostic factors. In Korean ALM, the stage at detection tends to be more advanced than in Western superficial spreading melanoma, so the prognosis may be somewhat poorer.